BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 35276290)

  • 21. A cell-permeable Stat3 SH2 domain mimetic inhibits Stat3 activation and induces antitumor cell effects in vitro.
    Zhao W; Jaganathan S; Turkson J
    J Biol Chem; 2010 Nov; 285(46):35855-65. PubMed ID: 20807764
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PDSS1-Mediated Activation of CAMK2A-STAT3 Signaling Promotes Metastasis in Triple-Negative Breast Cancer.
    Yu TJ; Liu YY; Li XG; Lian B; Lu XX; Jin X; Shao ZM; Hu X; Di GH; Jiang YZ
    Cancer Res; 2021 Nov; 81(21):5491-5505. PubMed ID: 34408002
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Eucannabinolide, a novel sesquiterpene lactone, suppresses the growth, metastasis and BCSCS-like traits of TNBC via inactivation of STAT3.
    Zhu Z; Yuan J; Xu X; Wei Y; Yang B; Zhao H
    Neoplasia; 2021 Jan; 23(1):36-48. PubMed ID: 33217668
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Progestins induce transcriptional activation of signal transducer and activator of transcription 3 (Stat3) via a Jak- and Src-dependent mechanism in breast cancer cells.
    Proietti C; Salatino M; Rosemblit C; Carnevale R; Pecci A; Kornblihtt AR; Molinolo AA; Frahm I; Charreau EH; Schillaci R; Elizalde PV
    Mol Cell Biol; 2005 Jun; 25(12):4826-40. PubMed ID: 15923602
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bt354 as a new STAT3 signaling pathway inhibitor against triple negative breast cancer.
    Chen Y; Ji M; Zhang S; Xue N; Xu H; Lin S; Chen X
    J Drug Target; 2018 Dec; 26(10):920-930. PubMed ID: 29595328
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Osthole inhibits triple negative breast cancer cells by suppressing STAT3.
    Dai X; Yin C; Zhang Y; Guo G; Zhao C; Wang O; Xiang Y; Zhang X; Liang G
    J Exp Clin Cancer Res; 2018 Dec; 37(1):322. PubMed ID: 30577812
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Activation of STAT3 and Bcl-2 and reduction of reactive oxygen species (ROS) promote radioresistance in breast cancer and overcome of radioresistance with niclosamide.
    Lu L; Dong J; Wang L; Xia Q; Zhang D; Kim H; Yin T; Fan S; Shen Q
    Oncogene; 2018 Sep; 37(39):5292-5304. PubMed ID: 29855616
    [TBL] [Abstract][Full Text] [Related]  

  • 28. STAT3 as a potential therapeutic target in triple negative breast cancer: a systematic review.
    Qin JJ; Yan L; Zhang J; Zhang WD
    J Exp Clin Cancer Res; 2019 May; 38(1):195. PubMed ID: 31088482
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Osimertinib and pterostilbene in EGFR-mutation-positive non-small cell lung cancer (NSCLC).
    Bracht JWP; Karachaliou N; Berenguer J; Pedraz-Valdunciel C; Filipska M; Codony-Servat C; Codony-Servat J; Rosell R
    Int J Biol Sci; 2019; 15(12):2607-2614. PubMed ID: 31754333
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 6-Bromoindirubin-3'-oxime inhibits JAK/STAT3 signaling and induces apoptosis of human melanoma cells.
    Liu L; Nam S; Tian Y; Yang F; Wu J; Wang Y; Scuto A; Polychronopoulos P; Magiatis P; Skaltsounis L; Jove R
    Cancer Res; 2011 Jun; 71(11):3972-9. PubMed ID: 21610112
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 15-Lipoxygenase-1-enhanced Src-Janus kinase 2-signal transducer and activator of transcription 3 stimulation and monocyte chemoattractant protein-1 expression require redox-sensitive activation of epidermal growth factor receptor in vascular wall remodeling.
    Singh NK; Wang D; Kundumani-Sridharan V; Van Quyen D; Niu J; Rao GN
    J Biol Chem; 2011 Jun; 286(25):22478-88. PubMed ID: 21536676
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A novel small molecule, LLL12, inhibits STAT3 phosphorylation and activities and exhibits potent growth-suppressive activity in human cancer cells.
    Lin L; Hutzen B; Li PK; Ball S; Zuo M; DeAngelis S; Foust E; Sobo M; Friedman L; Bhasin D; Cen L; Li C; Lin J
    Neoplasia; 2010 Jan; 12(1):39-50. PubMed ID: 20072652
    [TBL] [Abstract][Full Text] [Related]  

  • 33. STAT3 and PD-L1 are negatively correlated with ATM and have impact on the prognosis of triple-negative breast cancer patients with low ATM expression.
    Song YM; Qian XL; Xia XQ; Li YQ; Sun YY; Jia YM; Wang J; Xue HQ; Gao GS; Wang XZ; Zhang XM; Guo XJ
    Breast Cancer Res Treat; 2022 Nov; 196(1):45-56. PubMed ID: 36056297
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phosphorylated STAT3 (Tyr705) as a biomarker of response to pimozide treatment in triple-negative breast cancer.
    Dees S; Pontiggia L; Jasmin JF; Mercier I
    Cancer Biol Ther; 2020 Jun; 21(6):506-521. PubMed ID: 32164483
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design, Synthesis, and Biological Activity of Marinacarboline Analogues as STAT3 Pathway Inhibitors for Docetaxel-Resistant Triple-Negative Breast Cancer.
    Byun WS; Lim H; Hong J; Bae ES; Lee SB; Kim Y; Lee J; Lee SK; Hong S
    J Med Chem; 2023 Feb; 66(4):3106-3133. PubMed ID: 36786551
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Growth-suppressive activity of raloxifene on liver cancer cells by targeting IL-6/GP130 signaling.
    Wang Y; Ma H; Zhao C; Liu T; Yan D; Jou D; Li H; Zhang C; Lü J; Li C; Lin J; Li S; Lin L
    Oncotarget; 2017 May; 8(20):33683-33693. PubMed ID: 28430601
    [TBL] [Abstract][Full Text] [Related]  

  • 37. VGLL4 interacts with STAT3 to function as a tumor suppressor in triple-negative breast cancer.
    Song H; Luo Q; Deng X; Ji C; Li D; Munankarmy A; Jian W; Zhao J; Fang L
    Exp Mol Med; 2019 Nov; 51(11):1-13. PubMed ID: 31748508
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Enhanced sensitivity of pancreatic cancer cells to concurrent inhibition of aberrant signal transducer and activator of transcription 3 and epidermal growth factor receptor or Src.
    Jaganathan S; Yue P; Turkson J
    J Pharmacol Exp Ther; 2010 May; 333(2):373-81. PubMed ID: 20100905
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activation of GPER suppresses migration and angiogenesis of triple negative breast cancer via inhibition of NF-κB/IL-6 signals.
    Liang S; Chen Z; Jiang G; Zhou Y; Liu Q; Su Q; Wei W; Du J; Wang H
    Cancer Lett; 2017 Feb; 386():12-23. PubMed ID: 27836733
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 17-hydroxy-jolkinolide B inhibits signal transducers and activators of transcription 3 signaling by covalently cross-linking Janus kinases and induces apoptosis of human cancer cells.
    Wang Y; Ma X; Yan S; Shen S; Zhu H; Gu Y; Wang H; Qin G; Yu Q
    Cancer Res; 2009 Sep; 69(18):7302-10. PubMed ID: 19706767
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.